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Background: Allergic bronchopulmonary aspergillosis
(ABPA) is a disabling lung disease caused by aspergillus
fumigatus; a saprophytic mold was the most important
opportunistic fungal pathogen in humans. ABPA occurs
mainly in asthmatics and patients with cystic ﬁbrosis (CF).
We aimed to determine ABPA prevalence among these
patients over a period of 2 years at the main referral center
for immunological disorders in Iran.
Methods: All patients with asthma (47 cases) and CF
patients (27 cases) with the pulmonary manifestations sus-
pected to ABPA were referred to Immunology, Asthma and
Allergy Research Institute from December 2005 to January
2008. They were screened for ABPA with an aspergillus fumi-
gatus skin test. Patients with positive the skin test were
suspected to have ABPA if they met the followed crite-
ria: serum total IgE concentration of >1000 ng/ml, positive
speciﬁc IgE and IgG in their serum against A. fumigatus
evaluated with ImmunoCAP and/or RAST assay, proximal or
central bronchiectasis seen on the high-resolution CT (HRCT)
scan.
Results: During our study from 74 patients screened for
ABPA, 28 patients (37.8%) were found to be positive; 40.4%
in asthmatic patients (19 cases), and 33.3% in CF patients (9
cases). Among them, 21 patients had positive sputum culture
of aspergillus.
Conclusion: ABPA is a disease with the clinical signs of
asthma which delay of the diagnosis can lead to ﬁbrosis
and respiratory failure. The present study indicated that
ABPA was prevalent in persistent asthmatic and CF patients
respectively. It is advisable that the ABPA diagnostic tests
were performed for all suspected patients and prompt treat-
ment in these patients was strongly suggested for prevention
of their disease progress.
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Background: Vancomycin is a glycopeptide antibiotic that
kills gram positive bacteria by interfering with cell wall
synthesis. The necessity for monitoring serum vancomycin
concentrations (SVC) has recently been noticed at many
institutions because original concerns for nephorotoxicity
have been largely alleviated. We evaluated the SVCs mon-
itoring in pediatric patients, in an effort to identify the
variables affecting vancomycin pharmacokinetics; the sub-
therapeutic or toxic range.
Methods: We reviewed the medical records of all patients
older than 60 days of age admitted to Children Medi-
cal Center who were received interavenous vancomycin
between July 2003 and December 2005. Details of van-
comycin therapy, dosage and blood sampling times were
obtained. Because pharmacokinetic determination for chil-
dren with cancer may be different, this group was evaluated
separately.
Results: During the study, 167 infants and children with-
out cancer and 42 cancerous patients, aged from 3 months
to 17.5 years were treated with vancomycin for the vari-
ous infections. In 93% children without cancer, peak SVCs
was in an adequate therapeutic range with the highest level
of 55g/ml and lowest of 8g/ml. For children with can-
cer, peak SVCs was below 10g/ml in 10% cases, and trough
values <5g/ml in 21% cases.
Conclusion: Vancomycin remains an effective antibiotic
with infrequent discontinuations due to adverse events.
Monitoring SVCs should be considered for patients with
cancer, neonates, abnormal renal function, those receiv-
ing concurrent nephrotoxic drugs such as aminoglycosides
and those receiving higher than usual dosages. This empir-
ical dosing method can construct safe and effective
vancomycin dosage regimens and help to reduce the toxi-
city.
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